On June 14, June 15, and June 16, 2017, TG Therapeutics, Inc. issued press releases announcing certain data regarding its clinical studies of TGR-1202 plus ibrutinib, TG-1101 in combination with TGR-1202 and bendamustine, TG-1101 plus ibrutinib (the GENUINE trial), and TGR-1202 in combination with TG-1101 and ibrutinib, respectively, at the 14th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland. Copies of the press releases are being filed as Exhibits 99.1, 99.2 and 99.3 and incorporated in this Item by reference.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press Release, dated June 14, 2017.

99.2 Press Release, dated June 15, 2017.

99.3 Press Release, dated June 16, 2017.

About TG Therapeutics, Inc. (NASDAQ:TGTX)

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.